Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.97
-0.04 (-0.36%)
At close: May 22, 2026, 4:00 PM EDT
10.99
+0.02 (0.18%)
After-hours: May 22, 2026, 5:28 PM EDT

Design Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
20.6220.3418.0321.1318.9811.05
Research & Development
58.1359.1344.3557.0648.6124.78
Total Operating Expenses
78.7679.4762.3878.1967.5935.83
Operating Income
-78.76-79.47-62.38-78.19-67.59-35.83
Interest Income
9.049.6812.811.33--
Other Non-Operating Income (Expense)
----4.290.3
Total Non-Operating Income (Expense)
9.049.6812.811.334.290.3
Pretax Income
-69.71-69.79-49.59-66.86-63.31-35.53
Net Income
-69.71-69.79-49.59-66.86-63.31-35.53
Net Income to Common
-69.71-69.79-49.59-66.86-63.31-35.53
Shares Outstanding (Basic)
585757565646
Shares Outstanding (Diluted)
585757565646
Shares Change (YoY)
3.25%1.31%1.08%0.50%21.27%190.80%
EPS (Basic)
-1.20-1.22-0.88-1.19-1.14-0.77
EPS (Diluted)
-1.20-1.22-0.88-1.19-1.14-0.77
Shares Outstanding
62.4460.456.7556.4755.955.44
Free Cash Flow
-54.12-54.55-43.45-58.82-52.24-30.92
Free Cash Flow Per Share
-0.93-0.95-0.77-1.05-0.94-0.67
EBITDA
-78.14-78.85-61.79-77.65-67.19-35.7
EBIT
-78.76-79.47-62.38-78.19-67.59-35.83
Updated Apr 28, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q